2018
500 Does Use of Manipulator for Endometrial Cancer Surgery Lead to Increased Use of Adjuvant Therapy?
Seifi F, Clark M, Menderes G, Silasi D, Azodi M. 500 Does Use of Manipulator for Endometrial Cancer Surgery Lead to Increased Use of Adjuvant Therapy? Journal Of Minimally Invasive Gynecology 2018, 25: s175. DOI: 10.1016/j.jmig.2018.09.512.Peer-Reviewed Original ResearchDoes the use of manipulator for endometrial cancer surgery lead to increased use of adjuvant therapy?
Clark M, Seifi F, Parkash V, Silasi D, Azodi M. Does the use of manipulator for endometrial cancer surgery lead to increased use of adjuvant therapy? Gynecologic Oncology 2018, 149: 93. DOI: 10.1016/j.ygyno.2018.04.213.Peer-Reviewed Original Research
2016
Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G, Clark M, Santin AD. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer. Discovery Medicine 2016, 21: 293-303. PMID: 27232515.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntineoplastic AgentsClass I Phosphatidylinositol 3-KinasesCyclin ECystadenocarcinoma, SerousEndometrial NeoplasmsEpothilonesExomeFemaleHumansMolecular Targeted TherapyMutationNeoplasm Recurrence, LocalOncogene ProteinsPrognosisProtein Kinase InhibitorsProtein Phosphatase 2RadioimmunotherapyReceptor, ErbB-2Sequence Analysis, DNASignal TransductionTOR Serine-Threonine KinasesTubulin ModulatorsTumor Suppressor Protein p53Uterine NeoplasmsVascular Endothelial Growth Factor AConceptsUterine serous carcinomaEndometrial cancerSerous carcinomaTreatment of USCPIK3CA/AKT/mTOREndometrial cancer casesRecent whole-exome sequencing studiesHER2/neu geneNovel therapeutic targetAkt/mTORBiologic therapyAggressive variantDismal prognosisAggressive subtypeWhole-exome sequencing studiesCancer casesTherapeutic targetSubsequent deathDriver mutationsNeu geneGain of functionCarcinomaTherapyCancerSequencing studies